CN106661061B - 一种芳基丙酸类化合物及其制药用途 - Google Patents
一种芳基丙酸类化合物及其制药用途 Download PDFInfo
- Publication number
- CN106661061B CN106661061B CN201680000788.3A CN201680000788A CN106661061B CN 106661061 B CN106661061 B CN 106661061B CN 201680000788 A CN201680000788 A CN 201680000788A CN 106661061 B CN106661061 B CN 106661061B
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- salt
- acid
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 108
- 239000002253 acid Substances 0.000 title claims abstract description 12
- -1 sulphonic acid ester Chemical class 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000036592 analgesia Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 235000006109 methionine Nutrition 0.000 claims description 5
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical class CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 206010034464 Periarthritis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 235000014304 histidine Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 235000005772 leucine Nutrition 0.000 claims description 2
- 235000018977 lysine Nutrition 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000000323 shoulder joint Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 150000001484 arginines Chemical class 0.000 claims 1
- 235000015177 dried meat Nutrition 0.000 claims 1
- 150000002411 histidines Chemical class 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960002373 loxoprofen Drugs 0.000 abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 13
- 230000002829 reductive effect Effects 0.000 abstract description 9
- 150000002148 esters Chemical class 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 3
- 230000000146 antalgic effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000012360 testing method Methods 0.000 description 39
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 20
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- 238000001819 mass spectrum Methods 0.000 description 19
- 238000001228 spectrum Methods 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- BZCGWAXQDLXLQM-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O.ClP(Cl)(Cl)=O BZCGWAXQDLXLQM-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008354 sodium chloride injection Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WPGUUPJOAVPZBQ-UHFFFAOYSA-N [Cl].OP(O)(O)=O Chemical compound [Cl].OP(O)(O)=O WPGUUPJOAVPZBQ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000002521 alkyl halide group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 125000005631 S-sulfonamido group Chemical group 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OBSLWIKITOYASJ-AZEWMMITSA-N (2r,3s,4s,5r,6s)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical compound CN[C@@H]1[C@H](O)O[C@@H](CO)[C@H](O)[C@H]1O OBSLWIKITOYASJ-AZEWMMITSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical class OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NPVGYYAHLQAASP-UHFFFAOYSA-N 1-methyl-2-piperidin-1-ylpiperidine Chemical compound CN1CCCCC1N1CCCCC1 NPVGYYAHLQAASP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KCCKTIKZOIPZTG-UHFFFAOYSA-N 3-methylbutyl carbonochloridate Chemical compound CC(C)CCOC(Cl)=O KCCKTIKZOIPZTG-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YOQOZEWAUBOAPW-UHFFFAOYSA-N CCCCl=S(=O)=O Chemical compound CCCCl=S(=O)=O YOQOZEWAUBOAPW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical group [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- DAQOAQIMURJUJJ-UHFFFAOYSA-N N1(CCNCC1)C1=NC(N=C1)=O Chemical compound N1(CCNCC1)C1=NC(N=C1)=O DAQOAQIMURJUJJ-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 238000001935 peptisation Methods 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种芳基丙酸类化合物及其制药用途。本发明是以洛索洛芬在代谢过程中最具活性的醇代谢物为母核,制备了一系列磷酸酯、磺酸酯、碳酸酯、氨基酸酯等衍生物。所得衍生物能够增强抗炎镇痛的药效,减轻毒性反应,具有良好的代谢动力学性质。同时,也大大降低了药物对胃肠道的刺激作用,提高了病人用药顺应性,是一种颇具潜力的非甾体抗炎镇痛药物。
Description
技术领域
本发明涉及药物化学领域,具体涉及一种芳基丙酸类衍生物及其可药用盐,以及在非甾体类抗炎药的治疗领域中的应用。
背景技术
洛索洛芬钠(Loxoprofen Sodium)是一种对环氧化酶COX-1和COX-2均有抑制作用的消炎镇痛药。作为首个被合成的芳基丙酸类的前体型的非甾体抗炎药,洛索洛芬钠的疗效主要表现为镇痛作用显著,消炎、解热作用与其他同类药疗效相当。临床试验表现为口服后在人体内代谢为trans-OH型药物,同时在肝和血浆中浓度分布比其他部位高,之后便迅速转变为葡萄糖类结合物,最后以尿液的形式排出体外。洛索洛芬钠的镇痛效果比酮洛芬、吲哚美辛、萘普生要强10-20倍,还具有作用效果迅速且显著、毒副作用小、临床应用范围广等优点。
经过长期临床实践,早先被视为“完美”的COX-2特异性抑制剂也逐步暴露出如下问题:(1)疗效并未增加,(2)不良反应并未减少;(3)导致溃疡率短期内降低,长期使用无差异;(4)严重的心肌梗塞出现。因此,如何寻找毒副作用小的、更为安全有效的非甾体抗炎药成为业界研发的热点之一。
前药设计是药物开发中的常用策略之一。前体药物多含有酯键,其在体内可被酯酶或具有水解活性的类酯酶水解为活性药物分子。前药设计通常是为了提高原型药物的水溶性等理化性质,改善原药吸收效率,提高代谢稳定性,或是降低原药的毒副作用。
发明内容
本发明中根据洛索洛芬在体内活性生成的反式醇代谢物为母体,以反式环戊醇上的手性羟基为出发点,设计并制备了一系列的酯类衍生物,如磷酸酯、磺酸酯、碳酸酯、氨基酸酯等。
本发明提供一种如式I结构的芳基丙酸类衍生物,以及其药学上可接受的盐、水合物或溶剂合物,
其中,取代基A选自:
其中,G1或G2各自独立地表示羟基、直链或支链的C1~C6烷烃或直链或支链的C1~C6烷氧基;或G1、G2环合成含有杂原子的五元环、六元环或七元环;
G3或G4各自独立地表示氢、羟基、直链或支链的C1~C6烷烃、直链或支链的C1~C6烷氧基或苯基;或G3、G4环合成含有杂原子的五元环、六元环或七元环;
m=2或3;
n=0~6;
E为CH、C(CH3)或N;
或者,取代基A选自氨基酸去掉羧基中的羟基后余下的基团。
优选的,式I结构化合物的盐选自钠盐、钙盐、锌盐、镁盐、葡甲胺盐、赖氨酸盐、精氨酸盐、组氨酸盐或氨丁三醇盐。特别优选的,盐型选自钠盐、精氨酸盐、赖氨酸盐或氨丁三醇盐。
在一种优选方案中,G1或G2各自独立地表示羟基、C1~C5烷烃或C1~C5烷氧基。
在一种优选方案中,G3或G4各自独立地表示氢、羟基、C1~C5烷烃或苯基;或G3、G4环合成含有氮原子的五元环、六元环或七元环。
优选的,当取代基A选自:
时,
m选自2或3,
n选自0、1、2、3或4;
E选自CH、C(CH3)或N;
G1或G2各自独立地选自羟基、甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、甲氧基、乙氧基、丙氧基、异丙基氧基、异丁基氧基、叔丁基氧基或正戊基氧基;
G3或G4各自独立地选自氢、甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或苯基;或者G3、G4环合成含有氮原子的五元环、六元环或七元环。
本发明中,基团中,m为2时,该基团为当m为3时,该基团为其所形成的式I化合物是环状的磷酸酯。
优选的,当取代基A是氨基酸去掉羧基中的羟基后余下的基团时,所述氨基酸选自甘氨酸、赖氨酸、精氨酸、组氨酸、半胱氨酸、苯丙氨酸、脯氨酸、天冬氨酸、亮氨酸、丙氨酸或甲硫氨酸。
优选地,本发明式I化合物,可选自a组、b组、c组、d组、e组、f组中的下列化合物:
进一步优选地,本发明式I化合物,选自下列化合物:
更进一步优选地,本发明式I化合物,选自下列化合物:
本发明还提供了式I化合物的合成方法,即化合物从组a到组f的制备方法。
当式I化合物中取代基A为反应式如下所示,
将式II化合物在碱性条件下与磷酰氯起始物,即进行缩合反应即得。所述碱性条件可使用无机碱,例如氢氧化钠、碳酸钾;或有机碱,例如三乙胺,二异丙基乙胺。所述磷酰氯起始物,可以购买市售品,也可以采用相应的烷基醇与三氯氧磷制备得到。
当式I化合物中取代基A为具体地,反应式如下所示,
其中,2-氯-2-氧-1,3,2-二氧磷杂环己烷的制备可以通过三氯氧磷在低温下与1,3-丙二醇的环合反应制得,详见“具体实施方式”部分。
当式I化合物中取代基A为反应式如下所示,
将式II化合物在碱性条件下与磺酰氯起始物,即进行缩合反应即得;所述碱性条件选自氢氧化钠,碳酸钾,三乙胺或二异丙基乙胺。
当起始原料是牛磺酸时,还需要增加氨基的上保护基和脱除保护基的步骤。
不常见的磺酰氯的合成如下所示,
当式I化合物中取代基A为反应式如下所示,
将式II化合物在碱性条件下与碳酰氯起始物,即进行缩合反应即得。所述碱性条件选自氢氧化钠,碳酸钾,三乙胺或二异丙基乙胺。碳酰氯起始物可由相应的醇化物在三光气(BTC)的作用下制得,
当式I化合物中取代基A为反应式如下所示,
将式II化合物在碱性条件下与羧基酰氯起始物,即进行缩合反应即得。所述碱性条件选自氢氧化钠,碳酸钾,三乙胺或二异丙基乙胺。羧基酰氯起始物可由相应的羧基化物在氯化亚砜的作用下下制得,
当取代基A为氨基酸的羧基对应的酰基部分的结构,可通过Boc保护基或Cbz保护基对氨基进行保护后,再采用多胎合成中常用的缩合剂,如DCC,DIC,HOBT,进行缩合反应,最后脱除氨基保护基即得。这是本领域技术人员熟知的方法,详见“具体实施方式”部分。
除非另外说明,在说明书和权利要求中使用的以下术语具有下面讨论的含义:
“烷基”表示1‐20个碳原子的饱和的脂烃基,包括直链和支链基团(本申请书中提到的数字范围,例如“1‐20”或“C1~C20”,是指该基团,此时为烷基,可以含1个碳原子、2个碳原子、3个碳原子等,直至包括20个碳原子)。含1-5个碳原子的烷基称为低级烷基。当低级烷基没有取代基时,称其为未取代的低级烷基。更优选的是,烷基是有1‐10个碳原子的中等大小的烷基,例如甲基、乙基、丙基、2‐丙基、正丁基、异丁基、叔丁基、戊基等。最好是,烷基为有1‐4个碳原子的低级烷基,例如甲基、乙基、丙基、2‐丙基、正丁基、异丁基或叔丁基等。烷基可以是取代的或未取代的。当是取代的烷基时,该取代基优选是一或多个,更优选1‐3个,最优选1或2个取代基,它们独立地优选自以下的基团:卤素、羟基、低级烷氧基、芳基、芳氧基、杂芳基、杂脂环基。
“芳基”表示1至12个碳原子的全碳单环或稠合多环基团,具有完全共轭的π电子系统。芳基的非限制性实例有苯基、萘基和蒽基。芳基可以是取代的或未取代的。当被取代时,取代基优选为一个或多个,更优选为一个、两个或三个,进而更优选为一个或两个,独立地选自由低级烷基、三卤烷基、卤素、羟基、低级烷氧基、巯基、(低级烷基)硫基、氰基、酰基、硫代酰基、O‐氨基甲酰基、N‐氨基甲酰基、O‐硫代氨基甲酰基、N‐硫代氨基甲酰基、C‐酰氨基、N‐酰氨基、硝基、N‐磺酰氨基、S‐磺酰氨基。优选地,芳基可选地被一个或两个取代基取代,取代基独立地选自卤素、低级烷基、三卤烷基、羟基、巯基、氰基、N‐酰氨基、单或二烷基胺基、羧基或N‐磺酰氨基。
“杂环基”表示单环或稠合环基团,它为饱和或不饱基团,一般在环中具有5到9个环原子,其中一个或两个环原子是选自N、O或S(O)m(其中m是0至2的整数)的杂原子,其余环原子是C;例如含有杂原子的五元环、六元环或七元环。这些环可以具有一条或多条双键,但这些环不具有完全共轭的π电子系统。未取代的杂环基的非限制性实例有吡咯烷基、哌啶子基、哌嗪子基、吗啉代基、硫代吗啉代基、高哌嗪子基、四氢吡喃基、2,2‐二甲基‐1,3‐二氧戊环、哌啶子基、N‐甲基哌啶‐3‐基、哌嗪子基、N‐甲基吡咯烷‐3‐基、吡咯烷基、吗啉代基、硫代吗啉代基、硫代吗啉代‐1‐氧化物、硫代吗啉代‐1,1‐二氧化物、4‐乙氧羰基哌嗪子基、3‐氧代哌嗪子基、2‐咪唑啉酮、2‐吡咯烷酮、2‐氧代高哌嗪子基、四氢嘧啶‐2‐酮等。杂环基可以是取代的或未取代的。当被取代时,取代基优选为一个或多个、更优选为一个、两个或三个,进而更优选为一个或两个,独立地选自以下基团,包括:低级烷基、三卤烷基、卤素、羟基、低级烷氧基、巯基、(低级烷基)硫基、氰基、酰基、硫代酰基、O‐氨基甲酰基、N‐氨基甲酰基、O‐硫代氨基甲酰基、N‐硫代氨基甲酰基、C‐酰氨基、N‐酰氨基、硝基、N‐磺酰氨基、S‐磺酰氨基。
“羟基”表示‐OH基团。
“烷氧基”表示‐O‐(未取代的烷基)和‐O‐(未取代的环烷基)。代表性实例包括但不限于甲氧基、乙氧基、丙氧基、异丙基氧基、丁氧基、异丁基氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基、叔丁基氧基、正戊基氧基等。
“氨基酸去掉羧基中的羟基后余下的基团”,是指各种氨基酸中去掉羧基中的羟基后剩余的基团其中R为对应不同氨基酸的可变基团。
“药学上可接受的盐”表示保留母体化合物的生物有效性和性质的那些盐。这类盐包括:(1)与酸成盐,通过母体化合物的游离碱与无机酸或有机酸的反应而得,无机酸包括盐酸、氢溴酸、硝酸、磷酸、偏磷酸、硫酸、亚硫酸和高氯酸等,有机酸包括乙酸、三氟乙酸、丙酸、丙烯酸、己酸、环戊烷丙酸、羟乙酸、丙酮酸、草酸、(D)或(L)苹果酸、富马酸、马来酸、苯甲酸、羟基苯甲酸、γ-羟基丁酸、甲氧基苯甲酸、邻苯二甲酸、甲磺酸、乙磺酸、萘-1-磺酸、萘-2-磺酸、对甲苯磺酸、水杨酸、酒石酸、柠檬酸、乳酸、肉桂酸、十二烷基硫酸、葡糖酸、谷氨酸、天冬氨酸、硬脂酸、扁桃酸、琥珀酸或丙二酸等。(2)存在于母体化合物中的酸性质子被金属离子代替或者与有机碱配位化合所生成的盐,金属例子例如碱金属离子、碱土金属离子或铝离子,有机碱例如乙醇胺、二乙醇胺、三乙醇胺、氨丁三醇、N-甲基葡糖胺、奎宁等。
本发明还提供一种药物组合物,包含本发明所述的式I化合物和药用辅料。本发明的药物组合物可采用本领域公知的药用辅料通过常规方法制得。
本发明所述的药物组合物的制剂形式可以是固体制剂、半固体制剂,以及液体制剂,具体剂型可以是,例如片剂、栓剂、颗粒剂、胶囊剂、微囊剂、丸剂、膏剂、注射液(水针或输液)、冻干粉针剂、乳剂、混悬剂,溶胶剂,凝胶剂,乳膏剂,巴布剂。特别优选的制剂剂型选自片剂,胶囊剂,注射液,粉针剂,凝胶剂,乳膏剂,软膏剂,或巴布剂。
对于固体制剂而言,常规药用辅料包括填充剂、粘合剂、崩解剂、润滑剂。填充剂包括淀粉、乳糖、甘露醇、微晶纤维素;粘合剂包括淀粉、乳糖、甘露醇、微晶纤维素;崩解剂包括交联纤维素钠、交联聚维酮、低取代的羟丙甲基纤维素;润滑剂包括硬脂酸镁、滑石粉、聚乙二醇、十二烷基硫酸镁、微粉硅胶、滑石粉;药用辅料还可以包括着色剂、甜味剂。
对于液体制剂尤其是注射制剂而言,赋形剂选自乳糖、葡萄糖、甘露醇、甘氨酸、右旋糖苷;抗氧化剂选自氨基酸或其盐、亚硫酸盐、硫代硫酸盐;酸碱调节剂选自磷酸、乳酸、盐酸、枸橼酸以及氢氧化钠或氢氧化钾;渗透压调节剂选自氯化钠或葡萄糖;金属离子络合剂选自依地酸钙钠或依地酸二钠;助溶剂和稳定剂选自氨丁三醇,精氨酸,甲硫氨酸,半胱氨酸,抗坏血酸,柠檬酸钠。
本发明所述的药物组合物可以制成片剂、颗粒剂或胶囊剂的剂型。其中,片剂可以是普通片剂、分散片、泡腾片、缓释片、控释片或肠溶片,胶囊剂可以是普通胶囊、缓释胶囊、控释胶囊或肠溶胶囊。
本发明所述的药物组合物可以制成半固体制剂的形式,例如:凝胶剂,乳膏剂,巴布剂,透皮贴剂,膜剂,涂膜剂。当该药物组合物的剂型是软膏或乳膏时,软膏基质为水溶性基质,例如聚乙二醇类(PEG4000,PEG6000,PEG600等);乳膏基质为油包水型,或水包油型;油相为硬脂酸,石蜡,植物油或高级醇;乳化剂选自钙皂,羊毛脂,多元醇的脂肪酸酯,脂肪酸山梨坦类,优选的乳化剂是司盘80,或单硬脂酸甘油酯。在上述的软膏和乳膏的制备过程中,还可根据需要添加促渗剂,保湿剂,防腐剂,稳定剂等。
本发明所述的组合物可以制成外用的凝胶制剂,其包含有主药成分和凝胶基质。其中,凝胶基质选自卡波姆,聚乙烯吡咯烷酮,聚乙二醇,甲基纤维素,乙基纤维素,羟丙基纤维素,羧甲基纤维素钠,羟丙基甲纤维素,另外还可根据需要添加透皮促进剂,保湿剂,pH调节剂,防腐剂,稳定剂等。
本发明上述的药物化合物或其组合物可以用于在制备治疗下列疾病的药物中的医药用途,所述疾病包括但不限于各种炎症或各种情况或疾病引起的疼痛,特别选自:类风湿关节炎,骨性关节炎,腰痛症,肩关节周围炎,颈肩腕综合征的消炎和/或镇痛,手术后、外伤后或拔牙后的镇痛和/或消炎,急性上呼吸道炎(包括伴有或不伴有急性支气管炎的急性上呼吸道炎)解热和/或镇痛。
本发明以洛索洛芬在代谢过程中最具活性的醇代谢物为母核,制备了一系列磷酸酯、磺酸酯、碳酸酯、氨基酸酯等衍生物。所得衍生物能够增强抗炎镇痛的药效,减轻毒性反应,具有良好的代谢动力学性质。同时,也大大降低了药物对胃肠道的刺激作用,提高了病人用药顺应性,是一种颇具潜力的非甾体抗炎镇痛药物。
附图说明
附图1是化合物a-1的质谱图(正离子模式)。
附图2是化合物a-1的质谱图(负离子模式)。
附图3是实施例24的结果示意图。
具体实施方式
下面结合具体实施例对本发明技术方案作进一步说明。
本发明涉及的母核结构,即式II化合物,是根据文献“TetrahedronAsymmetry,2011,
22:1125-1132”中的实验方法制得。
实施例1化合物a-1的合成
使用氯磷酸的制备方法:式II化合物25g溶于无水乙腈70mL中,加入二异丙基乙胺13g,降温至-5~0℃,缓慢滴加氯磷酸12g的无水二氯甲烷溶液20mL,滴毕,保温搅拌1h,缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水150mL和二氯甲烷150mL搅拌,静置分层,浓缩二氯甲烷层,残余物用甲醇/乙酸乙酯重结晶,得到白色固体14g。
其中,氯磷酸的结构是其制备参考专利文献US4992429A1的说明书第6页中有关“Methyl(S)-4-(chloromethoxyphosphinyl)-3(tert-butyldiphenylsiloxy)butyrate”的合成方法制得。
质谱ESI-MS:m/z=329.5,[M+H]+,详见附图1。
核磁氢谱1H-NMR:δppm 7.23(d,2H),7.15(d,2H),4.9(br,2H),3.86(m,1H),3.65(m,1H),2.74(m,1H),2.46(m,1H),2.0(m,2H),1.9-1.6(m,5H),1.47(d,3H)。
实施例2化合物a-1的合成
使用三氯氧磷的制备方法:式II化合物7.2g溶于无水四氢呋喃100mL中,加入吡啶14mL,降温冷却,内温维持在-10至-15℃间,滴加三氯氧磷10mL溶于四氢呋喃30mL中的溶液,滴毕,0-5℃搅拌1h,移出至室温下,补加2mL三氯氧磷,室温搅拌至反应完全,TLC监控的展开剂为乙酸乙酯:冰醋酸=10:1,反应完毕,抽滤,滤液滴入到保温在0-5℃的纯水约600mL中,滴毕,室温25-30℃搅拌1h,加入乙酸乙酯300mL搅拌0.5h,静置分层,有机相用纯水、饱和食盐水洗涤,无水硫酸钠干燥,浓缩至干,残余物用甲醇/乙酸乙酯重结晶,得到白色固体5.9g。
质谱ESI-MS:m/z=327.1,[M-H]-,详见附图2。
核磁碳谱13C NMR(CDCl3):δppm 18.2,21.5,29,6,34.0,39.5,44.7,49.5,78.3,127.3,137.8,140.1,180.1。
实施例3化合物a-3的合成
参照实施例1的方法来进行制备,不同之处是滴加氯磷酸二乙酯的无水二氯甲烷溶液。
质谱ESI-MS m/z=385.6,[M+H]+。
核磁氢谱1H-NMR:δppm 7.25(d,2H),7.16(d,2H),4.04(m,4H),3.85(m,1H),3.64(m,1H),2.74(m,1H),2.46(m,1H),2.03(m,2H),1.93-1.66(m,5H),1.55(m,6H),1.44(d,3H)。
实施例4化合物a-6的合成
参照实施例1的方法来进行制备,不同之处是滴加氯磷酸二正丁酯的无水二氯甲烷溶液。
质谱ESI-MS m/z=441.4,[M+H]+。
核磁氢谱1H-NMR:δppm7.24(d,2H),7.12(d,2H),4.07(m,4H),3.80(m,1H),3.65(m,1H),2.77(m,1H),2.49(m,1H),2.04(m,2H),1.90-1.67(m,5H),1.66(m,4H),1.49(d,3H),1.39(m,4H),1.11(m,6H)。
实施例5化合物b-1的合成
2-氯-2-氧-1,3,2-二氧磷杂环戊烷的制备:将三氯化磷16g溶于二氯甲烷20mL,室温下加入1,2-乙二醇5g,滴加完毕,室温搅拌2h,减压蒸去溶剂,残余物减压蒸馏,收集50-53℃/3.0Kpa的馏分,所得无色液体溶于无水甲苯25mL,室温搅拌下通入氧气12h,减压蒸馏,收集81-85℃/6.0Kpa馏分,得到2-氯-2-氧-1,3,2-二氧磷杂环戊烷约9.2g。
式II化合物12.3g溶于无水四氢呋喃50mL中,加入三乙胺6.5g,降温至-5~0℃,缓慢滴加上述所得磷酰氯约7.2g的无水二氯甲烷溶液25mL,滴毕,保温搅拌1h后,再缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水200mL和乙酸乙酯20mL搅拌,静置分层,乙酸乙酯层浓缩所得残余物用异丙醇重结晶,得到白色固体约10.4g。
质谱ESI-MS m/z=355.3,[M+H]+。
核磁氢谱1H-NMR:δppm7.26(d,2H),7.13(d,2H),4.45(m,4H),3.82(m,1H),3.65(m,1H),2.78(m,1H),2.46(m,1H),2.09(m,2H),1.93-1.64(m,5H),1.47(d,3H)。
实施例6化合物b-2的合成
2-氯-2-氧-1,3,2-二氧磷杂环己烷的制备:将三氯氧磷8.0g溶于甲苯12mL,室温下滴加1,3-丙二醇4.1g,滴加完毕,室温搅拌2h,减压蒸去溶剂,残余物中加入无水乙醚40mL,0℃冷藏12h,过滤析出固体,无水乙醚重结晶得到白色固体约3.5g。
式II化合物12.5g溶于无水二氧六环40mL,加入无水碳酸钾7g,降温至-5~0℃,缓慢滴加上述所得磷酰氯7.5g的无水二氯甲烷溶液25mL,滴毕,保温搅拌1h后,再缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水和乙酸乙酯搅拌,静置分层,乙酸乙酯层浓缩所得残余物用甲醇/叔丁基醚重结晶,得到白色固体8.9g。
质谱ESI-MS m/z=369.4,[M+H]+。
核磁氢谱1H-NMR:δppm7.23(d,2H),7.17(d,2H),4.03(m,4H),3.90(m,1H),3.63(m,1H),2.71(m,1H),2.48(m,1H),2.16(m,2H),2.06(m,2H),1.93-1.65(m,5H),1.48(d,3H)。
实施例7化合物c-2的合成
式II化合物12.8g溶于无水四氢呋喃45mL,加入三乙胺6.8g,降温至-5~0℃,缓慢滴加丙基磺酰氯7.9g的无水二氯甲烷溶液25mL,滴毕,保温搅拌1h后,再缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水200mL和乙酸乙酯200mL搅拌,静置分层,乙酸乙酯层浓缩所得残余物用乙醇/乙酸乙酯重结晶,得到白色固体9.2g。
质谱ESI-MS m/z=355.7,[M+H]+。
核磁氢谱1H-NMR:δppm7.26(d,2H),7.13(d,2H),3.86(m,1H),3.67(m,1H),3.11(m,2H),2.76(m,1H),2.49(m,1H),2.02(m,2H),1.91-1.64(m,5H),1.62(m,2H),1.46(d,3H),1.09(m,3H)。
实施例8化合物c-6的合成
参照实施例7的方法来进行制备,不同之处是滴加苄基磺酰氯的无水二氯甲烷溶液
质谱ESI-MS m/z=403.9,[M+H]+。
核磁氢谱1H-NMR:δppm 7.39(m,2H),7.22(d,2H),7.18(m,3H),7.14(d,2H),4.31(m,2H),3.87(m,1H),3.65(m,1H),2.73(m,1H),2.49(m,1H),2.05(m,2H),1.91-1.65(m,5H),1.47(d,3H)。
实施例9化合物c-8的合成
2-(二甲基胺基)乙基-1-磺酰氯的制备方法:在反应瓶中加入氯化亚砜30mL,搅拌下分批加入2-(二甲基胺基)乙基-1-醇9g,回流4-5h,蒸去氯化亚砜,得到残余物淡黄色液体9.2g,将硫脲8g和上述淡黄色液体9.2g溶于95%乙醇150mL,加入四甲基氯化铵0.5g,回流反应24h,冷却,收集粗品,乙醇重结晶,得到白色晶体为该异硫脲盐酸盐,不经纯化,将该白色固体缓慢加入到5%稀硫酸溶液中,加入乙醚100mL,在冰水浴条件下缓慢加入5%次氯酸钠溶液,控制反应体系内温度在10-20℃之间,加毕继续反应0.5h,反应结束,分液所得有机相用无水硫酸钠干燥,浓缩至干得到2-(二甲基胺基)乙基-1-磺酰氯,溶于无水甲苯中备用。后续试验是参照实施例7的方法来进行制备,不同之处是滴加2-(二甲基胺基)乙基-1-磺酰氯的无水二氯甲烷溶液。
质谱ESI-MS m/z=384.8,[M+H]+。
核磁氢谱1H-NMR:δppm7.24(d,2H),7.13(d,2H),3.14(m,2H),3.83(m,1H),3.69(m,1H),2.75(m,2H),2.74(m,1H),2.49(m,1H),2.20(m,6H),2.06(m,2H),1.89-1.61(m,5H),1.47(d,3H)。
实施例10化合物c-10的合成
将牛磺酸12.5g溶于二甲基乙酰胺50mL和水50mL的混合溶剂中,加入无水碳酸钾14g,降温至-5~0℃,滴加约17.6g的Cbz-Cl的无水四氢呋喃30mL,滴毕,缓慢升至室温搅拌12h,TLC监控反应完全,过滤除去不溶物,浓缩至干,加入无水乙腈10mL和式II化合物20g,降温至0℃左右,滴加DCC 19.5g与DMAP 1.0g的四氢呋喃20mL,35-40℃搅拌10h,反应完全后,过滤除去不溶物,反应物浓缩至干,加入适量甲醇溶剂和5%重量的钯碳,常压氢化反应6h,反应结束,过滤,浓缩物加入水200mL和乙酸乙酯200mL,静置分层,乙酸乙酯层浓缩所得残余物用甲醇/乙酸乙酯重结晶两遍,得到白色固体10.5g。
质谱ESI-MS m/z=356.7,[M+H]+。
核磁氢谱1H-NMR:δppm7.24(d,2H),7.16(d,2H),3.89(m,1H),3.64(m,1H),3.27(m,2H),3.05(m,2H),2.74(m,1H),2.47(m,1H),2.05(m,2H),1.97-1.60(m,5H),1.61(s,2H),1.47(d,3H)。
实施例11化合物d-2的合成
将式II化合物12.4g溶于无水四氢呋喃50mL,加入三乙胺6g,降温至-5~0℃,缓慢滴加氯甲酸乙酯6g的无水二氯甲烷溶液20mL,滴毕,保温搅拌1h,缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水100mL和乙酸乙酯100mL搅拌,静置分层,乙酸乙酯层用5%碳酸氢钠溶液50mL洗涤,干燥,浓缩所得残余物用乙醇/乙酸乙酯重结晶,得到白色固体7.3g。
质谱ESI-MS m/z=321.8,[M+H]+。
核磁氢谱1H-NMR:δppm7.25(d,2H),7.17(d,2H),4.26(m,2H),3.89(m,1H),3.64(m,1H),2.78(m,1H),2.48(m,1H),2.07(m,2H),1.90-1.67(m,5H),1.458(d,3H),1.35(m,3H)。
实施例12化合物d-9的合成
参照实施例11的方法来进行制备,不同之处是滴加氯甲酸异戊酯的无水四氢呋喃溶液。
质谱ESI-MS m/z=363.5,[M+H]+。
核磁氢谱1H-NMR:δppm7.25(d,2H),7.14(d,2H),4.22(m,2H),3.91(m,1H),3.69(m,1H),2.74(m,1H),2.48(m,1H),2.05(m,2H),1.93(m,1H),1.9-1.6(m,5H),1.59(m,2H),1.47(d,3H),1.08(m,1H)。
实施例13化合物d-10的合成
参照实施例11的方法来进行制备,不同之处是滴加氯甲酸苄酯的无水四氢呋喃溶液。
质谱ESI-MS m/z=383.5,[M+H]+。
核磁氢谱1H-NMR:δppm 7.34-7.36(m,5H),7.24(d,2H),7.14(d,2H),4.85(m,2H),3.89(m,1H),3.63(m,1H),2.74(m,1H),2.47(m,1H),2.06(m,2H),1.91-1.65(m,5H),1.47(d,3H)。
实施例14化合物e-1的合成
将式II化合物12.3g溶于无水乙腈60mL中,加入二异丙基乙胺7g,降温至-5~0℃,缓慢滴加乙酰氯4g的无水甲苯溶液20mL,滴毕,保温搅拌1h,缓慢升至室温搅拌2h,TLC监控反应完全,减压除去反应溶剂,加水100mL和乙酸乙酯100mL搅拌,静置分层,乙酸乙酯层用5%碳酸氢钠溶液洗涤,干燥,浓缩所得残余物用甲醇/乙酸乙酯重结晶,得到白色固体8.8g。
质谱ESI-MS m/z=291.6,[M+H]+。
核磁氢谱1H-NMR:δppm7.23(d,2H),7.16(d,2H),3.89(m,1H),3.68(m,1H),2.77(m,1H),2.49(m,1H),2.10(m,3H),2.02(m,2H),1.91-1.64(m,5H),1.45(d,3H)。
实施例15化合物e-8的合成
参照实施例14的方法来进行制备,不同之处是滴加特戊酰氯的无水甲苯溶液。
质谱ESI-MS m/z=333.7,[M+H]+。
核磁氢谱1H-NMR:δppm7.24(d,2H),7.16(d,2H),3.80(m,1H),3.66(m,1H),2.75(m,1H),2.49(m,1H),2.06(m,2H),1.90-1.62(m,5H),1.48(d,3H),1.29(s,9H)。
实施例16化合物e-10的合成
将氯化亚砜20mL加入反应瓶中,缓慢加入苯乙酸7.2g,搅拌均匀,加热回流3h,减压浓缩反应液至干,溶于无水甲苯,得到苯乙酰氯的无水甲苯溶液,备用
参照实施例14的方法来进行制备,不同之处是滴加苯乙酰氯的无水甲苯溶液。
质谱ESI-MS m/z=367.4,[M+H]+。
核磁氢谱1H-NMR:δppm 7.26-7.28(m,5H),7.24(d,2H),7.14(d,2H),3.85(m,1H),3.67(m,1H),3.38(m,2H),2.76(m,1H),2.47(m,1H),2.03(m,2H),1.90-1.61(m,5H),1.47(d,3H)。
实施例17化合物f-1的合成
将Boc保护氨基的甘氨酸10g投入到反应瓶中,加入无水乙腈50mL,搅拌溶解,加入式II化合物12.5g与DMAP 0.5g,降温至0-5℃,滴加DCC约10g的无水乙腈溶液30mL,滴毕,升至室温反应12h,过滤,浓缩后残余物中加入二氯甲烷15mL和三氟乙酸15mL的等体积混合溶液30mL,0-5℃反应2h,TLC监控反应完全,浓缩反应液至干,异丙醇/乙酸乙酯重结晶两遍,得到白色固体11.8g。
质谱ESI-MS m/z=306.4,[M+H]+。
核磁氢谱1H-NMR:δppm 7.25(d,2H),7.11(d,2H),3.86(m,1H),3.65(m,1H),3.48(m,2H),2.75(m,1H),2.49(m,1H),2.08(m,2H),1.91-1.63(m,5H),1.49(d,3H)。
实施例18化合物f-3的合成
参照实施例17的方法来进行制备,不同之处是以Boc保护氨基的甲硫氨酸为原料,制备式II化合物的甲硫氨酸酯。
质谱ESI-MS m/z=380.6,[M+H]+。
核磁氢谱1H-NMR:δppm7.24(d,2H),7.15(d,2H),3.81(m,1H),3.68(m,1H),3.41(m,1H),2.75(m,1H),2.61(m,2H),2.48(m,1H),2.17(m,2H),2.07(s,3H),2.01(m,2H),1.92-1.64(m,5H),1.47(d,3H)。
实施例19化合物f-4的合成
参照实施例17的方法来进行制备,不同之处是以Boc保护氨基的苯丙氨酸为原料,制备式II化合物的苯丙氨酸酯。
质谱ESI-MS m/z=396.5,[M+H]+。
核磁氢谱1H-NMR:δppm7.25(d,2H),7.17(d,2H),7.14-7.16(m,5H),4.17(m,1H),3.89(m,1H),3.64(m,1H),3.54(m,1H),3.30(m,1H),2.74(m,1H),2.46(m,1H),2.03(m,2H),1.92-1.64(m,5H),1.47(d,3H)。
本发明中的a-2,a-4~5,c-1,c-3~5,c-7,c-9,d-1,d-3~8,e-2~7,e-9,f-2等化合物均可按上述各合成方法通过采用不同的原料制得。所得化合物的质谱数据收集如下。
化合物编号 | [M+H]<sup>+</sup> | 化合物编号 | [M+H]<sup>+</sup> | 化合物编号 | [M+H]<sup>+</sup> |
a-2 | 357.6 | a-4 | 413.5 | a-5 | 441.4 |
c-1 | 341.3 | c-3 | 369.2 | c-4 | 369.5 |
c-5 | 382.7 | c-7 | 370.3 | c-9 | 411.4 |
d-1 | 307.2 | d-3 | 335.2 | d-4 | 349.3 |
d-5 | 363.4 | d-6 | 349.5 | d-7 | 335.2 |
d-8 | 348.3 | e-2 | 305.3 | e-3 | 319.3 |
e-4 | 333.4 | e-5 | 347.3 | e-6 | 333.7 |
e-7 | 319.5 | e-9 | 347.3 | f-2 | 362.4 |
关于药物组合物方面,以化合物b-1、b-2为例,制备本发明所述药物组合物的制剂,具体如下。
实施例20式I衍生物的片剂制备
配方:
制备工艺:将原料药化合物b-1过100目筛,乳糖,淀粉,羧甲基淀粉钠过80目筛,将原料药与羧甲基淀粉钠,淀粉,乳糖,混合均匀,加入1.5%羧甲基纤维素钠溶液制得软材,30目制粒,60℃干燥1.5h,得干物料,加入硬脂酸镁,混合10min,24目整粒,压片,即得。
实施例21式I衍生物的注射剂制备
配方:
制备方法:将配方量的原料药化合物b-2溶于70%注射用水,加入配方量的精氨酸,调节溶液的pH=7.0-8.5,再用注射用水定容,向定容后的溶液中加入0.1%(g/ml)的活性炭吸附20min后过滤除炭,将溶液通过0.22μm的滤膜精滤,中间体检测含量合格后灌装成10ml每支,将灌装得到的半成品至于灭菌柜中121℃灭菌15min后,灯检合格后分装即得成品。
实施例22式I衍生物的凝胶剂制备
配方:
制备方法:将配方量的尼泊金丙酯溶于配方量丙二醇,乙二胺四乙酸二钠盐溶于适量蒸馏水中,混合两者,再加入配方量甘油,搅匀;将卡波姆940缓慢投入上述溶液中,不断搅拌,静置24h,得空白胶,备用。将氢氧化钠溶液在搅拌下缓慢加入空白胶中,调节pH6.0-6.5,将配方量的化合物b-1用适量蒸馏水溶解,不断搅拌下,加到调好pH值的空白胶中,最后加入配方量油酸搅匀。称重,补加蒸馏水至总重,分装。
实施例23药物引发的胃溃疡的形成
参考Biochemical Pharmacology,2004(67):575-585中记载的方法进行试验。
将试验用雄性大鼠(体重约200g)断食24h,口服给予试验化合物,使给药剂量与洛索洛芬相等的摩尔量,12h后摘除胃部,测定胃内部产生的溃疡面积。对全部溃疡的面积进行合计,作为溃疡系数。对比药物是洛索洛芬,剂量是40mg/Kg。新化合物b-1,化合物b-2的给药剂量是相当于洛索洛芬40mg/Kg的用量。
结果如下:洛索洛芬的溃疡系数为9.4(mm2),而化合物b-1的溃疡系数是2.2(mm2),化合物b-2的溃疡系数是2.4(mm2)。这表明,新化合物b-1,b-2几乎不形成副作用的溃疡,胃部的溃疡面积很小,溃疡系数很低。
实施例24药物引发胃溃疡的对比试验
使用Wister系雄性大鼠(体重180-200g),断食18h,口服等重量的试验化合物,8h后摘除胃,测定胃内部产生的溃疡面积。对全部溃疡的面积进行合计,作为溃疡系数。分别给予大鼠口服对比药物洛索洛芬,新化合物a-1,c-10,e-1,f-1,剂量都是20mg/Kg。试验结果如附图3所示。
实施例25镇痛试验(洛索洛芬和新化合物b-1,b-2的对小鼠扭体的抑制率)
对小鼠腹腔给药醋酸溶液后出现的扭体次数进行计数,并基于对照组计算扭体的抑制率。24只小鼠被分成了4个小组,每组6只。组A为对照组,给空白制剂;组B口服给予洛索洛芬40mg/Kg,组C、组D分别口服给予相当于洛索洛芬40mg/Kg剂量的化合物b-1,化合物b-2。在给药醋酸溶液60min前将被测化合物给药于小鼠,结果如表1所示。
表1扭体试验结果
组别 | 组A | 组B | 组C | 组D |
剂量(mg/Kg) | 0 | 40 | 40 | 40 |
扭体次数 | 42.1 | 22.1 | 15.6 | 17.2 |
抑制百分率(%) | 无 | 47 | 61 | 59 |
结果表明:化合物b-1与b-2的镇痛作用好于阳性药洛索洛芬。
实施例26镇痛试验(热板法)
取体重在18-22g的小鼠,每支小鼠放在55℃金属热板上,测定出现踢脚、舔后足、跳跃等疼痛反应所需潜伏期,取两次痛阈均值,为该小鼠痛阈均值,此值小于6秒或大于30秒者应剔除。取合格小鼠,随机分组,每组10只,溶媒对照组为0.5%CMC-Na,阳性对照组为洛索洛芬,试验组选用的化合物是化合物a-1,c-10,e-1,f-1。阳性对照组和试验组的使用剂量均为30mg/Kg。各组小鼠服药后,分别于60、90、120分钟时测定小鼠痛阈值。试验结果如表2所示。
表2热板试验结果
本发明中所指出的a组、b组、c组、d组、e组、f组的其他化合物也具有类似效果。
实施例27抗炎试验(给药角叉菜胶的肿胀率试验)
将试验用雄性大鼠(体重约200g)断食24h,口服给予试验化合物,给药剂量与洛索洛芬是相等的摩尔量,1h后,向左足跖皮下注射1%角叉菜胶,从而引起浮肿,该角叉菜胶溶于100微升的生理盐水中,给药角叉菜胶后每隔1h测量一次大鼠后爪的体积,计算后爪的体积增长率来作为肿胀率(%)。组A为对照组,给空白制剂;组B口服给予洛索洛芬40mg/Kg,组C,组D分别口服给予相当于洛索洛芬40mg/Kg剂量的化合物b-1,化合物b-2。各个组别在不同时间点的肿胀率(%)结果如表3所示,结果表明:相同剂量的新化合物b-1与b-2的抗炎效果好于阳性药洛索洛芬。
表3角叉菜胶试验结果
实施例28抗炎试验(小鼠耳二甲苯致炎实验)
取体重24-28g的小鼠,随机分组,每组10只,溶媒对照组为0.5%CMC-Na,阳性对照组为洛索洛芬,试验组选用的化合物是化合物a-1,c-10,e-1,f-1。阳性对照组和试验组的使用剂量均为30mg/Kg。各组小鼠分别给药后60分钟,将二甲苯0.05mL均匀滴于右耳廓,左耳对照,1小时后处死小鼠,用直径8mm打孔器在左、右耳同一部位打下圆耳片,称重,左右耳片重量差值即为肿胀程度。试验结果如表4所示。
表4二甲苯致炎试验结果
组别 | 肿胀程度(mg) | 抑制率(%) |
溶媒对照组 | 15.5 | 0 |
阳性对照组 | 11.4 | 26.45 |
a-1组 | 2.6 | 83.22 |
c-10组 | 4.2 | 72.90 |
e-1组 | 3.5 | 77.41 |
f-1组 | 3.8 | 75.48 |
本发明中所指出的a组、b组、c组、d组、e组、f组的其他化合物也具有类似效果。
实施例29化合物a-1注射液的局部毒性试验研究
(一)化合物a-1注射液的制备
将处方量的化合物a-1加入80%脱氧注射用水,40℃水浴条件下搅拌至全部溶解,用氢氧化钠或柠檬酸调节pH6.5-7.5,加入0.05%活性炭,减压抽滤,除去活性炭,溶液过0.22μm滤膜,灌装于每支20mg/10mL,30mg/10mL,40mg/10mL,或50mg/10mL的安瓿瓶中,121℃热压蒸汽灭菌10min。
(二)血管刺激性试验
依据《化学药物刺激性、过敏性和溶血性研究技术指导原则》,本次试验的药物浓度为4mg/mL,采用自身对照,左耳给药,右耳给予等量的0.9%氯化钠注射液,每天给药1次,连续给药3天,每次给药前、给药后,以及最后一次给药后24h、48h仔细观察给呀不为有无红斑、水肿等刺激性反应。最后一次给药48h后处死动物,去给药部位,作血管组织病理切片,检查血管时候有组织变性或坏死等刺激性反应。
试验结果:肉眼观察上述注射液组及0.9%氯化钠注射液组血管,在给药期及恢复期,均未见红斑、水肿、溃疡等刺激性症状;病理检查显示,每只兔耳的三个取材点均未见血管内皮细胞肿胀、坏死,血管腔清晰,管腔内无血栓,血管周围组织无炎症细胞浸润或出血等病变。因此,该注射液对兔耳血管无刺激性作用。
(三)溶血试验
依据《化学药物刺激性、过敏性和溶血性研究技术指导原则》,本次试验的药物浓度为4mg/mL。取试管7支,按下表一次加入2%的红细胞混悬液和0.9%氯化钠注射液,混匀后按表5加入不同体积的供试品初始溶液,第6,7管分别为阴性和阳性。摇匀后,置37℃恒温箱中,开始每隔15min观察一次,1h后,每隔1h观察1次,观察4h,判断溶液是否出现溶血或红细胞聚集现象。
表5溶血试验试管编号
试管编号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
2%红细胞悬液(mL) | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
氯化钠注射液(mL) | 2.4 | 2.3 | 2.2 | 2.1 | 2.0 | 2.5 | 0 |
蒸馏水(mL) | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 |
供试品(mL) | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0 | 0 |
试验结果:本次试验未见溶血作用,亦无红细胞凝聚现象。
实施例30试验药物在大鼠体内代谢速率的测定
试验方法:将对照药洛索洛芬以及试验药物(即化合物a-1,c-10,e-1,f-1)溶于生理盐水,配置得到10mg/mL的溶液。如遇不易完全溶清,则加入少量乙醇助溶。取体重180-220g的大鼠,随机分组,每组6只。按照20mg/Kg剂量,分别给予洛索洛芬组,a-1组,c-10组,e-1组,f-1组的大鼠,通过尾静脉注射药液。根据预设时间点,大鼠眼眶取血,收集血样,测定血药浓度,收集数据如表6所示。
表6大鼠体内代谢速率的试验结果
应当说明的是,以上所述仅为本发明的较佳实施例而已,并不用于限制本发明的范围。凡在本发明的精神和原则之内所作出的任何修改、等同的替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种如式I结构的芳基丙酸类化合物,以及其药学上可接受的盐,
其中,取代基A选自:
其中,G1或G2各自独立地表示羟基、直链或支链的C1~C6烷烃、直链或支链的C1~C6烷氧基;或G1、G2环合而成的A为m=2或3;
G3或G4各自独立地表示氢、羟基、直链或支链的C1~C6烷烃、直链或支链的C1~C6烷氧基或苯基;
n=0~6;
E为CH、C(CH3)或N;
或者,取代基A选自氨基酸去掉羧基中的羟基后余下的基团。
2.根据权利要求1所述的化合物,其特征在于,式I结构化合物的盐选自钠盐、钙盐、锌盐、镁盐、葡甲胺盐、赖氨酸盐、精氨酸盐、组氨酸盐或氨丁三醇盐。
3.根据权利要求1所述的化合物,其特征在于,G1或G2各自独立地表示羟基、C1~C5烷烃或C1~C5烷氧基;G3或G4各自独立地表示氢、羟基、C1~C5烷烃或苯基。
4.根据权利要求1所述的化合物,其特征在于,
当取代基A选自
n选自0、1、2、3或4;
E选自CH、C(CH3)或N;
G1或G2各自独立地选自羟基、甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、甲氧基、乙氧基、丙氧基、异丙基氧基、异丁基氧基、叔丁基氧基或正戊基氧基;
G3或G4各自独立地选自氢、甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或苯基。
5.根据权利要求1所述的化合物,其特征在于,当取代基A是氨基酸去掉羧基中的羟基后余下的基团时,所述氨基酸选自甘氨酸、赖氨酸、精氨酸、组氨酸、半胱氨酸、苯丙氨酸、脯氨酸、天冬氨酸、亮氨酸、丙氨酸或甲硫氨酸。
6.根据权利要求1所述的化合物,其特征在于,选自下列化合物:
7.根据权利要求1所述的化合物,其特征在于,选自下列化合物:
8.根据权利要求1所述的化合物,其特征在于,选自下列化合物:
9.一种药物组合物,其特征在于,包含如权利要求1-8中任一项所述的化合物,以及药学上可接受的辅料;该药物组合物的制剂形式选自片剂、胶囊剂、注射液、粉针剂、凝胶剂、乳膏剂、软膏剂或巴布剂。
10.权利要求1-8中任一项所述化合物在制备治疗下列疾病的药物中的医药用途,所述疾病选自:类风湿关节炎,骨性关节炎,腰痛症,肩关节周围炎,颈肩腕综合征的消炎和/或镇痛,手术后、外伤后或拔牙后的镇痛和/或消炎,急性上呼吸道炎解热和/或镇痛中的一种或几种。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015104327873 | 2015-07-22 | ||
CN201510432787 | 2015-07-22 | ||
PCT/CN2016/090764 WO2017012556A1 (zh) | 2015-07-22 | 2016-07-20 | 一种芳基丙酸类化合物及其制药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106661061A CN106661061A (zh) | 2017-05-10 |
CN106661061B true CN106661061B (zh) | 2019-06-11 |
Family
ID=57833786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680000788.3A Active CN106661061B (zh) | 2015-07-22 | 2016-07-20 | 一种芳基丙酸类化合物及其制药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106661061B (zh) |
WO (1) | WO2017012556A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111635315B (zh) * | 2019-03-01 | 2024-03-12 | 华创合成制药股份有限公司 | 一种解热镇痛药物及其制备方法和用途 |
CN111635309B (zh) * | 2019-03-01 | 2024-03-12 | 华创合成制药股份有限公司 | 一种新型解热镇痛药物及其制备方法和用途 |
CN110590848A (zh) * | 2019-09-10 | 2019-12-20 | 恒大新能源科技集团有限公司 | 阻燃添加剂及其制备方法和应用 |
CN113121331B (zh) * | 2019-12-31 | 2024-01-05 | 华创合成制药股份有限公司 | 具有环丙基的苯氧芳酸类化合物及其药学上可接受的盐,以及它们的制备方法和应用 |
CN114073669A (zh) * | 2020-08-13 | 2022-02-22 | 南京海融医药科技股份有限公司 | 一种含芳基丙酸类化合物的凝胶剂 |
CN114746394B (zh) * | 2020-09-09 | 2024-02-02 | 南京海融医药科技股份有限公司 | 一种芳基丙酸衍生物、药物组合物及其制备方法和应用 |
CN113429320A (zh) * | 2021-07-15 | 2021-09-24 | 老河口市天和科技有限公司 | 十五烷基磺酰氯的制备方法及含十五烷基磺酰氯的油鞣剂 |
CN115557839B (zh) * | 2021-12-23 | 2024-02-13 | 南京海融医药科技股份有限公司 | 一种包含芳基丙酸衍生物的脂肪乳剂及其制备方法 |
WO2023115511A1 (zh) * | 2021-12-24 | 2023-06-29 | 南京海融医药科技股份有限公司 | 一种芳基丙酸衍生物及其乳状制剂 |
CN117682966A (zh) * | 2022-04-19 | 2024-03-12 | 石家庄迪斯凯威医药科技有限公司 | 一种手性芳基丙酸衍生物及其药物组合物和用途 |
CN115232036A (zh) * | 2022-07-21 | 2022-10-25 | 南通大学 | 一种二苯乙烯多酚牛磺酸酯、制备方法及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014660A1 (en) * | 2011-07-22 | 2013-01-31 | Venantius Limited | Indane dimers for use in the treatment of autoimmune inflammatory disease |
-
2016
- 2016-07-20 CN CN201680000788.3A patent/CN106661061B/zh active Active
- 2016-07-20 WO PCT/CN2016/090764 patent/WO2017012556A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014660A1 (en) * | 2011-07-22 | 2013-01-31 | Venantius Limited | Indane dimers for use in the treatment of autoimmune inflammatory disease |
Non-Patent Citations (1)
Title |
---|
Species differences in metabolism of sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate (loxoprofen sodium), a new antiinflammatory agent;TANAKA, Yorihisa等;《Chemical & Pharmaceutical Bulletin》;19831231;第31卷(第10期);3656-3664页,尤其是3656-3657页 |
Also Published As
Publication number | Publication date |
---|---|
WO2017012556A1 (zh) | 2017-01-26 |
CN106661061A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106661061B (zh) | 一种芳基丙酸类化合物及其制药用途 | |
ES2741439T3 (es) | Compuestos aromáticos sustituidos | |
BR112017008198B1 (pt) | combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson | |
ES2832501T3 (es) | Inhibidor del ácido carboxílico URAT1 que contiene estructura de diarilmetano, método de preparación y uso del mismo | |
CN102149700A (zh) | 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物 | |
CN102228463A (zh) | 泰诺福韦的晶体 | |
CN109438371B (zh) | 一种甲基吡嗪衍生物精氨酸水合物 | |
WO2019218864A1 (zh) | 一种2-(α羟基戊基)苯甲酸的有机胺酯衍生物药物 | |
NO172939B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive estere av estramustin | |
CN103524559A (zh) | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 | |
RU2622105C2 (ru) | Кристаллическая форма соединения, используемая в качестве антагониста минералокортикоидного рецептора, и способ ее получения | |
CN111518040B (zh) | 一种甲基吡嗪衍生物-哌嗪共晶 | |
CN112110865B (zh) | 一种异烟酰胺阿西莫司共晶体ⅱ及其制备方法 | |
CN102190644A (zh) | 手性3-羟基吡啶-4-酮类衍生物及其合成和用途 | |
ES2876004T3 (es) | Formulaciones farmacéuticas que contienen derivados de 3-(4-cinamil-L-piperazinil) amino de 3-formilrifamicina S | |
CN102952138A (zh) | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 | |
WO2021032218A1 (zh) | 一种并环THRβ受体激动剂化合物及其制备方法和用途 | |
PT2066677E (pt) | Moduladores do receptor de pirido-oxazepina progesterona | |
CN106146612B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
CN111393342B (zh) | 一种蒜氨酸硫化氢供体化合物及其制备方法与运用 | |
CN116478050B (zh) | 一种手性芳基丙酸衍生物及其药物组合物和用途 | |
CN102757338A (zh) | 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途 | |
WO2024099382A1 (en) | Salts and solid forms of a compound having apj receptor activity | |
CN109134295B (zh) | 蒽二酮衍生物及其制备方法和应用 | |
WO2021223398A1 (zh) | 治疗肝病的晶型及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |